Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Climb Bio (CLYM) Non Operating Investment Income (2021 - 2026)

Climb Bio filings provide 6 years of Non Operating Investment Income readings, the most recent being -$278000.0 for Q1 2026.

  • Quarterly Non Operating Investment Income fell 205.7% to -$278000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$129000.0 through Mar 2026, down 145.1% year-over-year, with the annual reading at $412000.0 for FY2025, 1548.0% up from the prior year.
  • Non Operating Investment Income hit -$278000.0 in Q1 2026 for Climb Bio, down from -$34000.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $263000.0 in Q1 2023 and bottomed at -$398000.0 in Q1 2022.
  • Average Non Operating Investment Income over 5 years is $17500.0, with a median of $23500.0 recorded in 2022.
  • The largest annual shift saw Non Operating Investment Income crashed 2077.78% in 2024 before it soared 13050.0% in 2025.
  • Climb Bio's Non Operating Investment Income stood at $223000.0 in 2022, then tumbled by 95.96% to $9000.0 in 2023, then crashed by 2077.78% to -$178000.0 in 2024, then surged by 80.9% to -$34000.0 in 2025, then plummeted by 717.65% to -$278000.0 in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Non Operating Investment Income are -$278000.0 (Q1 2026), -$34000.0 (Q4 2025), and $151000.0 (Q3 2025).